The National Pharmaceutical Council has issued these guiding practices regarding the design of value-analysis frameworks that promote value in patient care and outcomes.
Click on the thumbnail to view the infographic or read the information below.
Assessment Process
Involve stakeholders throughout the entire process
Allow for public comment periods
Update assessments regularly to keep pace with innovation
Benefits
Include a broad array of factors that matter to patients and society
Consider individual treatment effects
View the benefits of a treatment over a long-term horizon
Costs
Consider all healthcare costs and offsets over time
Ensure costs are accurate and relevant to the user of the framework
Evidence
Use all high-quality evidence that is currently available
Gather and synthesize evidence in a transparent and robust manner, using accepted practices
Methodology
Focus assessments on all aspects of the healthcare system
Use established methods and transparent models and assumptions
Acknowledge uncertainty in input factors by reporting ranges around estimates
Dissemination & Utilization
Label assessments clearly for their intended use
Make assessments easy for users to interpret
Disseminate publicly only after assessments are finalized
Assessing the budget impact: Budget-impact assessments measure resource use, not value. Guiding practices should:
- Assess all aspects of care (such as hospitalization or doctor visits), not just medications
- Keep budget-impact and value assessments separate
- Consider a longer time horizon that includes all costs and cost offsets
- Acknowledge uncertainty in input factors by reporting ranges around estimates
Source: National Pharmaceutical Council, “Guiding Practices for Patient-Centered Value Assessment.” Information reprinted with permission.
